Andrews Research & Education Foundation and Vector Science and Therapeutics Announce Collaboration for the Clinical Evaluation and Development of Peptides for Sports Medicine and Regenerative Medicine Applications

Andrews Research & Education Foundation and Vector Science and Therapeutics Announce Collaboration for the Clinical Evaluation and Development of Peptides for Sports Medicine and Regenerative Medicine Applications

PR Newswire

Partnership brings together Foundation’s expertise in research and physician education with Company’s peptide formulation, pharma-grade manufacturing, and delivery capabilities

Livestreamed media briefing featuring Dr. James Andrews and Tommy Thompson set for 11 a.m. CST today

GULF BREEZE, Fla. and MEQUON, Wis., Nov. 18, 2026 /PRNewswire/ — Vector Science and Therapeutics (TSXV: PAIN) (“Vector” or the “Company”) – Dr. James Andrews, a world-renowned orthopedic surgeon and sports medicine pioneer, and Tommy G. Thompson, the former U.S. Secretary of Health and Human Services, four-term Governor of Wisconsin, and current Chairman of Vector, today announced a collaboration between the Andrews Research & Education Foundation (AREF) and the Company to advance the clinical evaluation of peptides for physicians’ use in the practice of sports medicine and regenerative medicine. This partnership between industry and the medical research community is the first of its kind in the United States focused on musculoskeletal applications of peptides and aligns with the current movement toward much-needed regulation of peptide manufacturing and distribution.

https://vectorscience.co/

As part of the collaboration, AREF and the Company will design and initiate clinical programs to evaluate the use of Vector’s pharma-grade peptides for musculoskeletal applications, including approaches to accelerate repair of soft tissue following activity or injury; motivate muscle regeneration in the aging athlete, and mitigate the impact of degenerative osteoarthritis. AREF will contribute intellectual property and bench-top research from its staff at its Gulf Breeze facility, while Vector will formulate, supply, and test peptides for the clinical projects using current good manufacturing practice (cGMP) consistent with applicable quality and regulatory requirements. Vector will also contribute specialized delivery-system development, prototyping, scale-up, manufacturing development, supply, testing and analytical services in its new Mequon, Wis., facility.

“Our goal is to bring rigorous research and clinical insight to important questions in sports and regenerative medicine,” said Dr. Andrews, President and Chairman of the Board at AREF. “By combining the Foundation’s research experience and clinical perspective with Vector’s capabilities, we can pursue projects grounded in scientific merit, patient need, and evidence. We have always led the way in developing new procedures and medical technology to help our patients. The use of peptides in medical practice is innovation that requires attention now, and we want to work closely with Vector to see that this is handled properly.”

In addition, AREF and the Company will develop physician education programs focused on peptide best practices and protocols. The programs will include courses for sports medicine fellows and residents, grand rounds, and multiple symposia offered through AREF’s expansive sports medicine network.

“The peptide marketplace needs trust, and that trust must be built on evidence, education, and quality,” said Mr. Thompson. “This collaboration creates a framework to bring together established sports medicine research expertise and disciplined peptide development and manufacturing practices. We believe that this winning combination can help move the field toward a more rigorous, evidence-based approach.”

Intellectual property developed through the collaboration, including new peptides, new medical applications, and intellectual property resulting from research and clinical trials, will be jointly owned by AREF and the Company. Vector will lead the commercialization of new products in alignment with its highly focused, direct-to-physician marketing activities.

“The relationship with AREF represents a pivotal moment for Vector and the medical community,” said Bill Jackson, CEO of Vector. “We bring a focus on supply integrity, manufacturing rigor, and quality assurance. Working with AREF enables us to build on these strengths through the collaborative initiatives to obtain clinical evidence, advance education, and bring innovation to medical practice just as Dr. Andrews has done for decades. Together, we aim to help establish a more trusted foundation for peptide development and contribute to the development of rigorous, evidence-based standards for this emerging area in sports medicine and regenerative medicine.”

Livestreamed Media Briefing Information

Date: Wednesday, Nov. 18, 2026

Time: 11 a.m. to 11:30 a.m. CST

Format: Live Zoom event originating in Gulf Breeze, Fla.

Pre-registration and event access: https://russopr.zoom.us/webinar/register/WN_N_YU_AHMT-yOZk4iSdK41w

Speakers: Dr. James Andrews, Tommy Thompson, Bill Jackson, Dr. Adam Anz, Dr. Josh Hackel

Discussion Moderator: Solomon Wilcots, sports broadcaster and former NFL player, team member of Russo Partners’ Sports-Health Alliance

Journalists and other audience members should use the Zoom link above to pre-register. Following registration, attendees will receive the information needed to access the live event.

Media Interview Scheduling and Coordination

Immediately following the briefing, from 11:30 a.m. CST until 12:30 p.m. CST on Wednesday, Dr. Andrews, Mr. Thompson, and other briefing participants will be available to conduct media interviews via Zoom or telephone. Interview requests and scheduling will be handled through the chat function during the Zoom event or by email using vectorpr@russopartnersllc.com. Journalists who are unable to conduct interviews during this window may request additional times, and Russo Partners will manage these requests individually.

Media Access to B-Roll Video Package

A broadcast-quality B-roll package is available to media outlets. Contact Vector’s media team at vectorpr@russopartnersllc.com to obtain access online. The package consists of footage of Vector’s manufacturing team at work in Mequon, Wis., and video soundbites about the collaboration from Dr. Andrews, Tommy Thompson, Bill Jackson, and Benjamin Nelson, Ph.D., Chief Operating Officer at Lyogenesis and Verlyrix.

About Dr. James Andrews

Over a career spanning more than five decades, Dr. Andrews has helped shape modern sports medicine through his work advancing arthroscopic surgical techniques and research into the prevention and treatment of knee, shoulder, and elbow injuries. Dr. Andrews co-founded the American Sports Medicine Institute and the Andrews Sports Medicine and Orthopedic Center in Birmingham, Alabama, and is the founder of Andrews Research and Education Foundation and the Andrews Institute in Gulf Breeze, Florida. Dr. Andrews is also the founder of Andrews Medicine. Dr. Andrews has played a leading role in research, education, and the development of sports medicine specialists. His patients have included Michael Jordan, Bo Jackson, Drew Brees, Roger Clemens, Jack Nicklaus, and John Smoltz. Dr. Andrews’ contributions to medicine have been recognized through his induction into the Alabama Sports Hall of Fame and Louisiana Sports Hall of Fame, the LSU Alumni Hall of Distinction, and the National Athletic Trainers’ Association President’s Award, among other honors.

About the Andrews Research & Education Foundation

The Andrews Research & Education Foundation (AREF), based in Gulf Breeze, Fla., focuses on advancing musculoskeletal research, injury prevention, surgical skills training, and physical rehabilitation. AREF operates specialized facilities, including a Biomechanics Lab, a Regenerative Medicine Center, and a Surgical Skills Lab, to support clinical trials, educate the next generation of sports medicine fellows, and improve outcomes for youth athletes, active-duty military personnel, veterans, and the broader community.

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing anatomically focused drug delivery technology and cGMP-manufactured Rx peptides for the sports medicine, regenerative medicine, pain management, and wound care markets. Vector’s peptides are made with pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) from qualified suppliers and are produced under current Good Manufacturing Practice (cGMP) and ISO-certified quality systems.

The Company’s product and intellectual property portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies. Vector is headquartered in Mequon, Wis. For more information, visit https://vectorscience.co/. Follow Vector on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information in this news release includes, but is not limited to, statements regarding the collaboration between AREF and the Company; the design, initiation, scope and conduct of research and clinical programs by AREF and the Company; the evaluation and potential use of the Company’s peptides in sports medicine, regenerative medicine and musculoskeletal applications; the development of physician education programs, best practices and protocols relating to peptides; the Company’s development, formulation, manufacture, testing, scale-up and supply of peptides and related delivery systems; the development and ownership of new intellectual property, peptides, medical applications and products arising from the collaboration; the Company’s ability to commercialize any products or technologies resulting from the collaboration; the regulatory environment with respect to peptides and the potential for the collaboration to advance evidence-based approaches to peptide development and use in sports medicine and regenerative medicine.

Forward-looking information is based on management’s current expectations, estimates, forecasts, beliefs and assumptions, including assumptions regarding the ability of the parties to successfully carry out the contemplated research, clinical and education programs; the scientific and clinical merits of the peptides and technologies to be evaluated; the availability of sufficient funding, personnel, facilities and other resources to carry out the collaboration; the Company’s ability to formulate, manufacture, test and supply peptides and related products in accordance with applicable quality and regulatory requirements; the ability of the parties to obtain any required ethics, regulatory or other approvals; the ability to successfully develop, protect and commercialize intellectual property and products resulting from the collaboration; and the continued cooperation of AREF and other researchers, physicians and third parties involved in the contemplated programs.

Such forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, the risks that research, preclinical or clinical results may not support the safety, efficacy or intended use of any peptide, product or technology being evaluated; clinical programs may be delayed, modified or discontinued or may not produce the anticipated results; required regulatory, ethics or other approvals may not be obtained on anticipated terms or timelines, or at all; applicable laws, regulations or regulatory policies relating to peptides, compounded drugs or investigational products may change or be interpreted in a manner adverse to the Company; the Company may be unable to manufacture, supply or scale products in accordance with applicable specifications, quality standards or regulatory requirements; the parties may not successfully develop or protect intellectual property arising from the collaboration; products or technologies developed through the collaboration may not receive required regulatory approvals or achieve physician, patient or market acceptance; the Company may not have sufficient capital or other resources to carry out its contemplated development and commercialization activities; and other risks and uncertainties described in the Company’s public disclosure documents available under its profile on SEDAR+ at https://www.sedarplus.ca.

Readers should be aware that the peptides and potential applications to be evaluated under the collaboration may be investigational and have not necessarily been approved by applicable regulatory authorities for the uses under evaluation. The collaboration is intended to generate scientific and clinical evidence concerning such potential applications, and no assurance can be given regarding the results of such research or whether any product or application will receive regulatory approval or be successfully commercialized.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. The forward-looking information contained in this news release is made as of the date of this news release, and the Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Photo availability: Photographs of Dr. James Andrews, Tommy Thompson, Bill Jackson, and AREF’s and Vector’s facilities are available to media outlets upon request.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/andrews-research–education-foundation-and-vector-science-and-therapeutics-announce-collaboration-for-the-clinical-evaluation-and-development-of-peptides-for-sports-medicine-and-regenerative-medicine-applications-302943283.html

SOURCE Vector Sciences & Therapeutics